medical decision support 1 medical decision support 2
Subscribe Sign In

Predictors of Zhou et al for Cancer-Specific Mortality in a Male with Recurrent Prostate Cancer

Description

Zhou et al identified factors predictive of cancer-specific mortality in males with recurrent prostate cancer. These can help identify a patient who may benefit from closer monitoring and more aggressive management. The authors are from Brigham and Women's Hospital, Dana Farber Cancer Institute, University of Connecticut, Uniformed Services University, University of California San Francisco, and Duke University.


 

Patient selection: Patient with PSA failure following definitive therapy

 

Parameters:

(1) type of definitive therapy (radical prostatectomy vs radiation therapy)

(2) Gleason score of the original tumor

(3) PSA doubling time after PSA failure

 

For a patient who had undergone radical prostatectomy, the only predictor was the PSA doubling time after PSA failure.

 

PSA Doubling Time

Prostate Cancer Specific Mortality at 5 Years

>= 3 months

1%

< 3 months

31%

 

For a patient who had undergone radiation therapy, the predictors were PSA doubling time and the Gleason score.

 

PSA Doubling Time

Gleason Score

Prostate Cancer Specific Mortality at 5 Years

< 3 months

8 to 10

75%

< 3 months

2 to 7

35%

>= 3 months

8 to 10

15%

>= 3 months

2 to 7

4%

 


To read more or access our algorithms and calculators, please log in or register.

Specialty